Literature DB >> 10089966

Inhibitory effect of erythromycin on interleukin-8 secretion from exudative cells in the nasal discharge of patients with chronic sinusitis.

H Suzuki1, Y Asada, K Ikeda, T Oshima, T Takasaka.   

Abstract

OBJECTIVES: The mechanism of the efficacy of long-term low-dose macrolide therapy for chronic sinusitis is not fully understood. The authors studied the inhibitory effect of erythromycin on interleukin-8 (IL-8) secretion from exudative cells in the nasal discharge of patients with chronic sinusitis. STUDY DESIGN AND METHODS: Exudative cells in the nasal discharge were isolated from six patients with nonallergic chronic sinusitis. The cells, more than 90% of which were neutrophils, were incubated with or without erythromycin in the presence of 10 micrograms/mL of lipopolysaccharide. The IL-8 concentrations in the culture supernatants were measured by enzyme-linked immunoassay.
RESULTS: The amount of secreted IL-8 in the absence of erythromycin was 682 +/- 226 pg/10(6) cells/24 h. The IL-8 secretion was significantly reduced to 66 +/- 15% and 46 +/- 13% of the control in the presence of 10(-6) and 10(-5) M of erythromycin, respectively.
CONCLUSION: Erythromycin may act as a biologic modulator that inhibits IL-8 secretion from exudative cells and thereby blocks the vicious circle of neutrophil recruitment and IL-8 generation in the inflammatory site in chronic sinusitis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10089966     DOI: 10.1097/00005537-199903000-00012

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  5 in total

1.  Anti-inflammatory treatment of chronic rhinosinusitis: a shifting paradigm.

Authors:  Umur Hatipo; Israel Rubinstein
Journal:  Curr Infect Dis Rep       Date:  2007-05       Impact factor: 3.725

Review 2.  Anti-inflammatory treatment of chronic rhinosinusitis: a shifting paradigm.

Authors:  Umur Hatipoğlu; Israel Rubinstein
Journal:  Curr Allergy Asthma Rep       Date:  2008-04       Impact factor: 4.806

Review 3.  Anti-inflammatory therapies for cystic fibrosis-related lung disease.

Authors:  David P Nichols; Michael W Konstan; James F Chmiel
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

Review 4.  Treatment of chronic rhinosinusitis with low-dose, long-term macrolide antibiotics: an evolving paradigm.

Authors:  Umur Hatipoglu; Israel Rubinstein
Journal:  Curr Allergy Asthma Rep       Date:  2005-11       Impact factor: 4.919

5.  Prospective evaluation of clarithromycin in recurrent chronic rhinosinusitis with nasal polyps.

Authors:  Thiago Freire Pinto Bezerra; Rogério Pezato; Pâmella Marletti de Barros; Larissa Leal Coutinho; Leidianny Firmino Costa; Fabio Pinna; Richard Voegels
Journal:  Braz J Otorhinolaryngol       Date:  2019-11-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.